(E)-3-(4-chlorophenyl)-1-(2,4-dihydroxy-6-methoxyphenyl) prop-2-en-1-one | 1207843-42-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: (E)-3-(4-chlorophenyl)-1-(2,4-dihydroxy-6-methoxyphenyl) prop-2-en-1-one
• 英文别名: (E)-3-(4-chlorophenyl)-1-(2,4-dihydroxy-6-methoxyphenyl)prop-2-en-1-one
• CAS: 1207843-42-2
• 化学式: C₁₆H₁₃ClO₄
• 分子量: 304.73
• InChiKey: ZXVVIVDMNYJIQC-QPJJXVBHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-羟基-4,6-二甲氧基苯乙酮 在 aluminum (III) chloride 、 三氯化硼 、 potassium carbonate 、 potassium hydroxide 作用下， 以 乙醇 、 二氯甲烷 、 水 、 二甲基亚砜 、 氯苯 为溶剂， 生成 (E)-3-(4-chlorophenyl)-1-(2,4-dihydroxy-6-methoxyphenyl) prop-2-en-1-one
  参考文献：
  名称：

  设计，合成和生物评价二甲基小豆蔻（DMC）衍生物作为P糖蛋白介导的多药耐药逆转剂。

  摘要：

  背景：过去十年来，P-糖蛋白（P-gp）被认为是肿瘤细胞多药耐药性（MDR）的重要因素，可以通过抑制Pgp逆转MDR来解决。因此，开发P-gp抑制剂是一种有效的策略。 目的：本研究在二甲基小豆蔻苷（DMC）的基础上，通过生物等位线设计进行了一系列衍生物的合成。随后，我们评估了它们作为潜在的P-糖蛋白（P-gp）介导的多药耐药性（MDR）药物的逆转活性。 方法：在40％KOH存在下，通过Claisen-Schmidt反应，由苯乙酮和相应的苯甲醛合成二甲基豆蔻苷衍生物。用MTT评估它们的体外细胞毒性和逆转活性。此外，通过阿霉素（DOX）积累，蛋白质印迹和伤口愈合分析对化合物B4进行了深入评估。 结果与讨论：结果表明，化合物B2，B4和B6具有MDR反向剂的效力，而固有的细胞毒性很小。同时，这些化合物还显示出抑制MCF-7和MCF-7 / DOX细胞迁移的能力。此外，选择了最多的化合物B4进行进一步的研究，它促进了DOX在MCF-7

  DOI：

  10.2174/1570180817999200531162015

文献信息

• [EN] COMPOUNDS, THEIR SYNTHESES, AND THEIR USES<br/>[FR] COMPOSÉS, LEUR SYNTHÈSE ET LEURS UTILISATIONS
  申请人：UNIV LOUISVILLE RES FOUND

  公开号：WO2010019861A1

  公开（公告）日：2010-02-18

  Embodiments of the present invention provide compounds (such as Formula (I) compounds, Formula (II) compounds, and various embodiments thereof). Compositions comprising those compounds are also provided. Methods for their preparation are included. Also, uses of the compounds are included, such as administering and treating diseases (e.g., cancer and infections).

  本发明实施例提供化合物（如式（I）化合物、式（II）化合物及其各种实施例）。还提供包含这些化合物的组合物。包括它们的制备方法。此外，还包括化合物的用途，如给药和治疗疾病（例如癌症和感染）。
• COMPOUNDS, THEIR SYNTHESES, AND THIER USES
  申请人：Hammond Gerald B.

  公开号：US20110190325A1

  公开（公告）日：2011-08-04

  Embodiments of the present invention provide compounds (such as Formula (I) compounds, Formula (II) compounds, and various embodiments thereof). Compositions comprising those compounds are also provided. Methods for their preparation are included. Also, uses of the compounds are included, such as administering and treating diseases (e.g., cancer and infections).

  本发明实施例提供化合物（例如公式（I）化合物、公式（II）化合物及其各种实施例）。还提供包含这些化合物的组合物。其中包括它们的制备方法。此外，还包括这些化合物的用途，例如用于治疗疾病（例如癌症和感染）的给药和治疗。
• In vitro and in vivo anti-Leishmania activity of polysubstituted synthetic chalcones
  作者：José C. Aponte、Denis Castillo、Yannick Estevez、German Gonzalez、Jorge Arevalo、Gerald B. Hammond、Michel Sauvain

  DOI：10.1016/j.bmcl.2009.11.033

  日期：2010.1

  The in vitro screening of 43 polysubstituted chalcones against Leishmania amazonensis axenic amastigotes, led to the evaluation of 9 of them in a macrophage-infected model with the two other most infectious Leishmania species prevalent in Peru (L. braziliensis and L. peruviana). The five most active and selective chalcones were studied in vivo, resulting on the identification of two chalcones with high reduction parasite burden percentages. (C) 2009 Elsevier Ltd. All rights reserved.
• Synthesis of Xanthohumol Analogues and Discovery of Potent Thioredoxin Reductase Inhibitor as Potential Anticancer Agent
  作者：Baoxin Zhang、Dongzhu Duan、Chunpo Ge、Juan Yao、Yaping Liu、Xinming Li、Jianguo Fang

  DOI：10.1021/jm5016507

  日期：2015.2.26

  The selenoprotein thioredoxin reductases (TrxRs) are attractive targets for anticancer drugs development. Xanthohumol (Xn), a naturally occurring polyphenol chalcone from hops, has received increasing attention because of its multiple pharmacological activities. We synthesized Xn and its 43 analogues and discovered that compound 13n displayed the highest cytotoxicity toward HeLa cells (IC50 = 1.4 mu M). Structure-activity relationship study indicates that the prenyl group is not necessary for cytotoxicity, and introducing electron-withdrawing group, especially on the meta-position, is favored. In addition, methylation of the phenoxyl groups generally improves the potency. Mechanistic study revealed that 13n selectively inhibits TrxR and induces reactive oxygen species and apoptosis in HeLa cells. Cells overexpressing TrxR are resistant to 13n insult, while knockdown of TrxR sensitizes cells to 13n treatment, highlighting the physiological significance of targeting TrxR by 13n. The clarification of the structural determinants for the potency would guide the design of novel potent molecules for future development.
• COMPOUNDS, THEIR SYNTHESES, AND THEIR USES
  申请人：University Of Louisville Research Foundation, Inc.

  公开号：EP2330906A1

  公开（公告）日：2011-06-15